PacBio to Increase MAS-Seq Engineering to 16S rRNA and Bulk RNA-Seq Solutions

Conclude-to-Stop Alternatives Prepared to Guidance Crucial Shopper Applications With Enhanced Cost Flexibility on Lengthy-Study Sequencing Systems

MENLO PARK, Calif., Feb. 7, 2023 /PRNewswire/ — PacBio (NASDAQ: PACB), a top developer of significant-high-quality, remarkably correct sequencing alternatives, these days announced the commencement of a method intended to expand Multiplexed Arrays Sequencing (MAS-Seq) for new assays on the Sequel II/IIe and Revio™ sequencing systems. This plan builds on the effective MAS-Seq concatenation technology introduced past year that enabled price-successful solitary-cell isoform sequencing.

The MAS-Seq engineering concatenates multiple shorter fragments which are then study on the system as just one prolonged HiFi examine. This extends the efficient throughput by up to 16-fold, where the throughput boost component is decided by the dimensions of the quick fragment. We believe that that extending MAS-Seq engineering to essential purposes such as bulk RNA sequencing and 16S rRNA will provide buyers with price-successful kitted alternatives and stop-to-stop program.

“Due to the fact our Oct announcement of the first MAS-Seq based mostly kit, the consumer need has been really encouraging, to the level that buyers have been asking us to grow the technologies to their beloved software,” reported Christian Henry, President and Chief Govt Officer at

Read More